Document is current
Any future updates will be listed below
-
Authors
Gidh-Jain, Madhavi
Parke, Tom
König, Franz
Spiertz, Cecile
Mesenbrink, Peter https://orcid.org/0000-0002-5624-6726
,
Baffert, Fabienne
Patrizi, Robert
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (853966)
- License Information
-
More Information
Article History
Received: 24 September 2023
Accepted: 4 March 2024
First Online: 21 March 2024
Declarations
:
: Not applicable.
: Not applicable.
: All WP2 team members declare that they (i) have provided or do provide ethical professional services to academic, biotechnology, or pharmaceutical clients and (ii) are active in national and international not-for-profit associations that encourage ethical professional practices. WP2 team members are either employees of the EFPIA partners and are paid by their employers to work on the project as contribution from EFPIA partners or are employees of Public partners that receive funding from IMI. They are all employees of their respective companies.For the 3.5-year duration of project, MG was the Sanofi representative on the CC&R TransCelerate team and, in 2023, the lead for the CC&R TransCelerate Master Protocol workstream.
